These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 34155340)

  • 1. Tumour irradiation combined with vascular-targeted photodynamic therapy enhances antitumour effects in pre-clinical prostate cancer.
    Sjoberg HT; Philippou Y; Magnussen AL; Tullis IDC; Bridges E; Chatrian A; Lefebvre J; Tam KH; Murphy EA; Rittscher J; Preise D; Agemy L; Yechezkel T; Smart SC; Kinchesh P; Gilchrist S; Allen DP; Scheiblin DA; Lockett SJ; Wink DA; Lamb AD; Mills IG; Harris A; Muschel RJ; Vojnovic B; Scherz A; Hamdy FC; Bryant RJ
    Br J Cancer; 2021 Aug; 125(4):534-546. PubMed ID: 34155340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen Deprivation Therapy Potentiates the Efficacy of Vascular Targeted Photodynamic Therapy of Prostate Cancer Xenografts.
    Kim K; Watson PA; Lebdai S; Jebiwott S; Somma AJ; La Rosa S; Mehta D; Murray KS; Lilja H; Ulmert D; Monette S; Scherz A; Coleman JA
    Clin Cancer Res; 2018 May; 24(10):2408-2416. PubMed ID: 29463549
    [No Abstract]   [Full Text] [Related]  

  • 3. Vascular-targeted Photodynamic Therapy in Unilateral Low-risk Prostate Cancer in Germany: 2-yr Single-centre Experience in a Real-world Setting Compared with Radical Prostatectomy.
    Flegar L; Buerk B; Proschmann R; Propping S; Groeben C; Baunacke M; Herout R; Huber J; Thomas C; Borkowetz A
    Eur Urol Focus; 2022 Jan; 8(1):121-127. PubMed ID: 33602642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bombesin Antagonist-Based Radiotherapy of Prostate Cancer Combined with WST-11 Vascular Targeted Photodynamic Therapy.
    Kim K; Zhang H; La Rosa S; Jebiwott S; Desai P; Kimm S; Scherz A; O'Donoghue JA; Weber WA; Coleman JA
    Clin Cancer Res; 2017 Jul; 23(13):3343-3351. PubMed ID: 28108545
    [No Abstract]   [Full Text] [Related]  

  • 5. TOOKAD(®) Soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer.
    Azzouzi AR; Barret E; Moore CM; Villers A; Allen C; Scherz A; Muir G; de Wildt M; Barber NJ; Lebdai S; Emberton M
    BJU Int; 2013 Oct; 112(6):766-74. PubMed ID: 24028764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medium-term Follow-up of Vascular-targeted Photodynamic Therapy of Localized Prostate Cancer Using TOOKAD Soluble WST-11 (Phase II Trials).
    Noweski A; Roosen A; Lebdai S; Barret E; Emberton M; Benzaghou F; Apfelbeck M; Gaillac B; Gratzke C; Stief C; Azzouzi AR
    Eur Urol Focus; 2019 Nov; 5(6):1022-1028. PubMed ID: 29661587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Permanent occlusion of feeding arteries and draining veins in solid mouse tumors by vascular targeted photodynamic therapy (VTP) with Tookad.
    Madar-Balakirski N; Tempel-Brami C; Kalchenko V; Brenner O; Varon D; Scherz A; Salomon Y
    PLoS One; 2010 Apr; 5(4):e10282. PubMed ID: 20421983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model.
    Philippou Y; Sjoberg HT; Murphy E; Alyacoubi S; Jones KI; Gordon-Weeks AN; Phyu S; Parkes EE; Gillies McKenna W; Lamb AD; Gileadi U; Cerundolo V; Scheiblin DA; Lockett SJ; Wink DA; Mills IG; Hamdy FC; Muschel RJ; Bryant RJ
    Br J Cancer; 2020 Sep; 123(7):1089-1100. PubMed ID: 32641865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic Antitumor Immunity by PD-1/PD-L1 Inhibition Is Potentiated by Vascular-Targeted Photodynamic Therapy of Primary Tumors.
    O'Shaughnessy MJ; Murray KS; La Rosa SP; Budhu S; Merghoub T; Somma A; Monette S; Kim K; Corradi RB; Scherz A; Coleman JA
    Clin Cancer Res; 2018 Feb; 24(3):592-599. PubMed ID: 28954788
    [No Abstract]   [Full Text] [Related]  

  • 10. Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localised prostate cancer using WST11-vascular-targeted photodynamic (VTP) therapy.
    Moore CM; Azzouzi AR; Barret E; Villers A; Muir GH; Barber NJ; Bott S; Trachtenberg J; Arumainayagam N; Gaillac B; Allen C; Schertz A; Emberton M
    BJU Int; 2015 Dec; 116(6):888-96. PubMed ID: 24841929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. WST11 Vascular Targeted Photodynamic Therapy Effect Monitoring by Multispectral Optoacoustic Tomography (MSOT) in Mice.
    Neuschmelting V; Kim K; Malekzadeh-Najafabadi J; Jebiwott S; Prakash J; Scherz A; Coleman JA; Kircher MF; Ntziachristos V
    Theranostics; 2018; 8(3):723-734. PubMed ID: 29344301
    [No Abstract]   [Full Text] [Related]  

  • 12. Follow-up of vascular-targeted photodynamic therapy in a real-world setting.
    Borkowetz A; Kwe J; Boehm K; Baunacke M; Herout R; Lucke M; Burcea A; Thomas C
    World J Urol; 2024 Jan; 42(1):55. PubMed ID: 38244089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Vascular targeted photodynamic therapy in low-risk prostate cancer. A literature review].
    Kleinclauss F; Frontczak A; Balssa L; Lebdai S; Azzouzi R
    Prog Urol; 2019; 29(8-9):393-401. PubMed ID: 31266699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal magnetic resonance imaging-based assessment of vascular changes and radiation response in androgen-sensitive prostate carcinoma xenografts under androgen-exposed and androgen-deprived conditions.
    Røe K; Seierstad T; Kristian A; Mikalsen LT; Mælandsmo GM; van der Kogel AJ; Ree AH; Olsen DR
    Neoplasia; 2010 Oct; 12(10):818-25. PubMed ID: 20927320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of localized prostate cancer using WST-09 and WST-11 mediated vascular targeted photodynamic therapy-A review.
    Kawczyk-Krupka A; Wawrzyniec K; Musiol SK; Potempa M; Bugaj AM; Sieroń A
    Photodiagnosis Photodyn Ther; 2015 Dec; 12(4):567-74. PubMed ID: 26467273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined OX40 Agonist and PD-1 Inhibitor Immunotherapy Improves the Efficacy of Vascular Targeted Photodynamic Therapy in a Urothelial Tumor Model.
    Alvim RG; Georgala P; Nogueira L; Somma AJ; Nagar K; Thomas J; Alvim L; Riegel A; Hughes C; Chen J; Reis AB; Lebdai S; Scherz A; Zanganeh S; Gardner R; Kim K; Coleman JA
    Molecules; 2021 Jun; 26(12):. PubMed ID: 34205347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic antitumor protection by vascular-targeted photodynamic therapy involves cellular and humoral immunity.
    Preise D; Oren R; Glinert I; Kalchenko V; Jung S; Scherz A; Salomon Y
    Cancer Immunol Immunother; 2009 Jan; 58(1):71-84. PubMed ID: 18488222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor immunity promoted by vascular occluding therapy: lessons from vascular-targeted photodynamic therapy (VTP).
    Preise D; Scherz A; Salomon Y
    Photochem Photobiol Sci; 2011 May; 10(5):681-8. PubMed ID: 21258718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erectile function after WST11 vascular-targeted photodynamic therapy for low-risk prostate cancer treatment.
    Chelly S; Maulaz P; Bigot P; Azzouzi AR; Lebdai S
    Asian J Androl; 2020; 22(5):454-458. PubMed ID: 31939351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Which technology to select for primary focal treatment of prostate cancer?-European Section of Urotechnology (ESUT) position statement.
    Ganzer R; Arthanareeswaran VKA; Ahmed HU; Cestari A; Rischmann P; Salomon G; Teber D; Liatsikos E; Stolzenburg JU; Barret E
    Prostate Cancer Prostatic Dis; 2018 Jun; 21(2):175-186. PubMed ID: 29743538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.